Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Wuhan Humanwell Innovative Drug Research And Development Center Limited Company manages a company patent portfolio in the Biotechnology & Pharmaceuticals sector. The portfolio has 3 pending office actions. These actions are distributed among 3 distinct examiners. The prosecution activity spans 2 distinct art units.
HASTINGS, ALISON AZAR is the busiest examiner for the portfolio, currently holding 1 busiest examiner pending action. This examiner is responsible for a portion of the company's 3 total pending office actions. With 3 distinct examiners and 2 distinct art units, the portfolio shows the distribution of examination assignments across the pending office actions. Practitioners must manage 3 separate examiner relationships while addressing the standards of 2 distinct art units. This variety in assignments may require different communication strategies within the Biotechnology & Pharmaceuticals technology area. Practitioners should monitor the 1 busiest examiner pending action for developments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| CHENG, KAREN | 1 | 76.3% | +26.7% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264424 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264424 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 22d overdue |
| 18728577 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | HASTINGS, ALISON AZAR | — |
| 18687190 | EP4 ANTAGONIST COMPOUND AS WELL AS SALT, POLYMORPH AND USE THEREOF | CHENG, KAREN | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728577 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | HASTINGS, ALISON AZAR | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18687190 | EP4 ANTAGONIST COMPOUND AS WELL AS SALT, POLYMORPH AND USE THEREOF | CHENG, KAREN | 1623 | §103§112DP | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18264424 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | Other | Final Rejection | 22d overdue | Pending | Aug 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial